المؤلفون: S. Caponi, Elisa Paolicchi, Daniela Campani, Pinuccia Faviana, Elisa Giovannetti, Godefridus J. Peters, Niccola Funel, Ugo Boggi, Amir Avan, Paola Pacetti, Enrico Vasile, Michele Reni, Mina Maftouh, Andrea Mambrini, Michele Milella, Vanja Vaccaro, Maurizio Cantore

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: Maftouh, M, Avan, A, Funel, N, Paolicchi, E, Vasile, E, Pacetti, P, Vaccaro, V, Faviana, P, Campani, D, Caponi, S, Mambrini, A, Boggi, U, Cantore, M, Milella, M, Peters, G J, Reni, M & Giovannetti, E 2014, ' A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients ', Pharmacogenomics, vol. 15, no. 5, pp. 609-618 . https://doi.org/10.2217/pgs.13.225Test
Università di Pisa-IRIS
Pharmacogenomics, 15(5), 609-618. Future Medicine Ltd.

مصطلحات موضوعية: Male, Antimetabolites, Antineoplastic, Prognostic factor, Pancreatic ductal adenocarcinoma, Antimetabolites, Locally advanced, macromolecular substances, Deoxycytidine, Promoter Regions, Cohort Studies, Genetic, Pancreatic cancer, Genetics, medicine, Humans, SNP, Enhancer of Zeste Homolog 2 Protein, Polymorphism, Promoter Regions, Genetic, Aged, Pharmacology, Polymorphism, Genetic, business.industry, EZH2, Polycomb Repressive Complex 2, DNA, Middle Aged, medicine.disease, Antineoplastic, Survival Analysis, Gemcitabine, Pancreatic Neoplasms, MicroRNAs, Treatment Outcome, Cohort, Disease Progression, Cancer research, Molecular Medicine, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bc8f783cd084710d92d4ab8ad3e724eTest
https://doi.org/10.2217/pgs.13.225Test

المؤلفون: Elisa Giovannetti, Laura L. Meijer, Jisce R. Puik, Geert Kazemier, Godefridus J. Peters

المساهمون: Surgery, Medical oncology laboratory, CCA - Target Discovery & Preclinial Therapy Development

المصدر: Meijer, L L, Puik, J R, Peters, G J, Kazemier, G & Giovannetti, E 2016, ' hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients ', The Oncologist, vol. 21, no. 12, pp. e4 . https://doi.org/10.1634/theoncologist.2016-0262Test
The Oncologist
The Oncologist, 21(12). AlphaMed Press

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Antimetabolites, Antineoplastic, medicine.medical_treatment, Treatment outcome, Equilibrative nucleoside transporter 1, Deoxycytidine, Disease-Free Survival, Cholangiocarcinoma, Equilibrative Nucleoside Transporter 1, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, Letters to the Editor, Aged, Chemotherapy, biology, business.industry, Middle Aged, Gemcitabine, 030104 developmental biology, Bile Duct Neoplasms, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, biology.protein, Biomarker (medicine), Female, business, Adjuvant, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2356f1bce196ea80a75555ea4263dae6Test
https://doi.org/10.1634/theoncologist.2016-0262Test

المؤلفون: Jacobus A. Burgers, Godefridus J. Peters, Egbert F. Smit, Elisa Giovannetti, Francesco Di Costanzo, Andrea Ardizzoni, Carmelo Tibaldi, Andrea Camerini, Fausto Barbieri, Marcello Tiseo, Andrew D. Vincent

المساهمون: Medical oncology laboratory, Pulmonary medicine, CCA - Innovative therapy, Tiseo, Marcello, Giovannetti, Elisa, Tibaldi, Carmelo, Camerini, Andrea, Di Costanzo, Francesco, Barbieri, Fausto, Burgers, Jacobus A., Vincent, Andrew, Peters, Godefridus J., Smit, Egbert F., Ardizzoni, Andrea

المصدر: Lung Cancer, 78(1), 92-99. Elsevier Ireland Ltd
Tiseo, M, Giovannetti, E, Tibaldi, C, Camerini, A, Di Costanzo, F, Barbieri, F, Burgers, J A, Vincent, A D, Peters, G J, Smit, E F & Ardizzoni, A 2012, ' Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin ', Lung Cancer, vol. 78, no. 1, pp. 92-99 . https://doi.org/10.1016/j.lungcan.2012.07.009Test

مصطلحات موضوعية: Male, Oncology, Cancer Research, Lung Neoplasms, non-small cell lung cancer (NSCLC), Pharmacology, Thymidylate synthase, Carboplatin, Antineoplastic Agent, Reduced Folate Carrier Protein, chemistry.chemical_compound, Gene Frequency, Glutamates, Retrospective Studie, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Allele, Aged, 80 and over, biology, Pharmacogenetic, Hazard ratio, Middle Aged, Treatment Outcome, Pemetrexed, Female, Glutamate, Human, medicine.drug, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Guanine, Genotype, Non-small cell lung cancer (NSCLC), Antineoplastic Agents, Polymorphism, Single Nucleotide, Internal medicine, medicine, Humans, Alleles, Methylenetetrahydrofolate Reductase (NADPH2), Aged, Neoplasm Staging, Retrospective Studies, Xeroderma Pigmentosum Group D Protein, Antineoplastic Combined Chemotherapy Protocol, business.industry, Proportional hazards model, Thymidylate Synthase, gamma-Glutamyl Hydrolase, MTHFR-C667T polymorphism, medicine.disease, Lung Neoplasm, chemistry, Methylenetetrahydrofolate reductase, biology.protein, business, Pharmacogenetics

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e75b870f6ebcd4b15db069e24f07cf1Test
https://doi.org/10.1016/j.lungcan.2012.07.009Test

المؤلفون: Ines J. Beumer, Elisa Giovannetti, Kees Smid, Robert Mauritz, Cees J. van Groeningen, Herbert M. Pinedo, Godefridus J. Peters

المساهمون: Medical oncology, Internal medicine, Medical oncology laboratory, CCA - Innovative therapy

المصدر: Mauritz, R, Giovannetti, E, Beumer, I J, Smid, K, van Groeningen, C J, Pinedo, H M & Peters, G J 2009, ' Polymorphisms in the Enhancer Region of the Thymidylate Synthase Gene Are Associated with Thymidylate Synthase Levels in Normal Tissues but Not in Malignant Tissues of Patients with Colorectal Cancer ', Clinical Colorectal Cancer, vol. 8, no. 3, pp. 146-154 . https://doi.org/10.3816/CCC.2009.n.024Test
Clinical Colorectal Cancer, 8(3), 146-154. Elsevier

مصطلحات موضوعية: Adult, Male, Colorectal cancer, Colon, Thymidylate synthase, Metastasis, Genotype, medicine, Humans, RNA, Messenger, RNA, Neoplasm, Allele, Gene, Aged, Aged, 80 and over, Polymorphism, Genetic, biology, Reverse Transcriptase Polymerase Chain Reaction, Liver Neoplasms, Gastroenterology, Rectum, Thymidylate Synthase, Middle Aged, medicine.disease, Prognosis, Primary tumor, Molecular biology, Phenotype, Enhancer Elements, Genetic, Treatment Outcome, Oncology, biology.protein, Cancer research, Female, Neoplasm Recurrence, Local, Colorectal Neoplasms

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::053976b58f3f2f3db5c3796910b595f6Test
https://doi.org/10.3816/ccc.2009.n.024Test

المؤلفون: Enrico Vasile, Carmelo Tibaldi, G. Leticia Leon, Elisa Giovannetti, Armida D'Incecco

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: Journal of Cancer Research and Clinical Oncology, 141(7), 1189-1194. Springer Verlag
Vasile, E, Tibaldi, C, Leon, G L, D'Incecco, A & Giovannetti, E 2015, ' Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients ', Journal of Cancer Research and Clinical Oncology, vol. 141, no. 7, pp. 1189-1194 . https://doi.org/10.1007/s00432-014-1880-3Test

مصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, CYP1B1, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Single-nucleotide polymorphism, Docetaxel, Polymorphism, Single Nucleotide, Biomarkers, Pharmacological, Polymorphism (computer science), Carcinoma, Non-Small-Cell Lung, Internal medicine, Tumor Cells, Cultured, medicine, Carcinoma, Humans, neoplasms, Genetic Association Studies, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Hematology, business.industry, General Medicine, Middle Aged, Prognosis, medicine.disease, body regions, Treatment Outcome, Chemotherapy, Adjuvant, Cytochrome P-450 CYP1B1, Female, Taxoids, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5595da0c67b8409b2e8a1b7b1b23d1Test
https://research.vumc.nl/en/publications/96018efa-575a-443a-b58a-d1486c35ebb8Test

المؤلفون: Clara Lemos, Gl Scheffer, G. Giaccone, Elisa Giovannetti, Carmelo Tibaldi, G.J. Peters, T. van der Straaten, H-J Guchelaar, Pa Zucali, Alfredo Falcone, Armando Santoro, Yg Assaraf, Romano Danesi, Armida D'Incecco

المساهمون: Medical oncology, Medical oncology laboratory, Pathology, CCA - Innovative therapy

المصدر: Pharmacogenomics, 12(2), 159-170
Lemos, C, Giovannetti, E, Zucali, P A, Assaraf, Y G, Scheffer, G L, van der Straaten, T, D'Incecco, A, Falcone, A, Guchelaar, H J, Danesi, R, Santoro, A, Giaccone, G, Tibaldi, C & Peters, G J 2011, ' Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients ', Pharmacogenomics, vol. 12, no. 2, pp. 159-170 . https://doi.org/10.2217/pgs.10.172Test
Pharmacogenomics
Pharmacogenomics, 12(2), 159-170. Future Medicine Ltd.

مصطلحات موضوعية: Male, Oncology, Lung Neoplasms, Abcg2, gefitinib, Genome-wide association study, NSCLC, Carcinoma, Non-Small-Cell Lung, Genotype, ATP Binding Cassette Transporter, Subfamily G, Member 2, Precision Medicine, pharmacogenetics, biology, Middle Aged, Neoplasm Proteins, Treatment Outcome, embryonic structures, Toxicity, Molecular Medicine, Female, medicine.drug, Diarrhea, medicine.medical_specialty, ABCG2, animal structures, Antineoplastic Agents, Article, Gefitinib, Internal medicine, Genetics, medicine, Humans, Lung cancer, Pharmacology, Polymorphism, Genetic, business.industry, Haplotype, toxicity, medicine.disease, respiratory tract diseases, lung cancer, Haplotypes, Quinazolines, Cancer research, biology.protein, ATP-Binding Cassette Transporters, sense organs, business, Pharmacogenetics, Genome-Wide Association Study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89d8dbdb68ab3323182687faf44033e8Test
https://doi.org/10.2217/pgs.10.172Test

المؤلفون: Ilaria Pastina, Sergio Ricci, Tristan M. Sissung, Romano Danesi, Douglas K. Price, William D. Figg, Cinzia Orlandini, Aldo Chioni, C. Cianci, Francesco Crea, Elisa Giovannetti

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: BMC Cancer, 10. BioMed Central
BMC Cancer
Pastina, I, Giovannetti, E, Chioni, A, Sissung, T M, Crea, F, Orlandini, C, Price, D K, Cianci, C, Figg, W D, Ricci, S & Danesi, R 2010, ' Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients ', BMC Cancer, vol. 10, pp. 511 . https://doi.org/10.1186/1471-2407-10-511Test
BMC Cancer, Vol 10, Iss 1, p 511 (2010)

مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, Cancer Research, Genotype, medicine.medical_treatment, CYP1B1, Antineoplastic Agents, Pharmacology, lcsh:RC254-282, Prostate cancer, Surgical oncology, Internal medicine, medicine, Genetics, Humans, pharmacogenetics, docetaxel, prostate cancer, Aged, Aged, 80 and over, Chemotherapy, Predictive marker, Polymorphism, Genetic, business.industry, Prostatic Neoplasms, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Regimen, Treatment Outcome, Docetaxel, Drug Resistance, Neoplasm, Cytochrome P-450 CYP1B1, Multivariate Analysis, Taxoids, Aryl Hydrocarbon Hydroxylases, business, Pharmacogenetics, medicine.drug, Research Article

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d4b7502b090bab3a294e49896ddfdcTest
https://research.vumc.nl/en/publications/e3d52b71-e2c3-4422-b169-fb26d797e27bTest

المؤلفون: Marco Del Chiaro, Jin Hyeok Hwang, Elisa Giovannetti, Sun-Whe Kim, Gyeong Hoon Kang, Joo Kyung Park, Godefridus J. Peters, Niccola Funel, Giuseppe Giaccone, Yong-Tae Kim, Leticia G. Leon, Johannes Voortman, Min A Kim, Seth M. Steinberg

المساهمون: Medical oncology, Medical oncology laboratory, CCA - Innovative therapy

المصدر: PLoS ONE, 5(5):e10630. Public Library of Science
PLoS ONE, Vol 5, Iss 5, p e10630 (2010)
Hwang, J H, Voortman, J, Giovannetti, E, Steinberg, S M, Leon, L G, Kim, Y T, Funel, N, Park, J K, Kim, M A, Kang, G H, Kim, S W, Del Chiaro, M, Peters, G J & Giaccone, G 2010, ' Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer ', PLoS ONE, vol. 5, no. 5, e10630, pp. e10630 . https://doi.org/10.1371/journal.pone.0010630Test
PLoS ONE

مصطلحات موضوعية: Male, Oncology, Pathology, medicine.medical_treatment, Gastroenterology and Hepatology/Pancreas, lcsh:Medicine, Cohort Studies, Recurrence, Medicine, lcsh:Science, Oligonucleotide Array Sequence Analysis, Multidisciplinary, Hazard ratio, Middle Aged, Gene Expression Regulation, Neoplastic, Treatment Outcome, Italy, Chemotherapy, Adjuvant, Fluorouracil, Biomarker (medicine), Female, Adjuvant, Research Article, Carcinoma, Pancreatic Ductal, medicine.drug, medicine.medical_specialty, Gastroenterology and Hepatology/Gastrointestinal Cancers, Oncology/Gastrointestinal Cancers, Disease-Free Survival, Pancreatic cancer, Internal medicine, Biomarkers, Tumor, Adjuvant therapy, Carcinoma, Humans, Molecular Biology, Genetics and Genomics/Cancer Genetics, Aged, Cell Proliferation, Proportional Hazards Models, Korea, business.industry, Proportional hazards model, lcsh:R, Reproducibility of Results, medicine.disease, Pancreatic Neoplasms, MicroRNAs, Drug Resistance, Neoplasm, Multivariate Analysis, lcsh:Q, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82084ac8872d14c0371f6226ddffd380Test
https://research.vumc.nl/en/publications/395c4790-f76e-41bb-9005-55a897b80fc6Test

المؤلفون: Pacetti, P., Elisa Giovannetti, Mambrini, A., Nannizzi, S., Orlandi, M., Tartarini, R., Del Freo, A., Del Tacca, M., Danesi, R., Cantore, M.

المساهمون: Medical oncology laboratory, CCA - Innovative therapy

المصدر: Anticancer Research, 29(5), 1835-1840. International Institute of Anticancer Research
Scopus-Elsevier
Pacetti, P, Giovannetti, E, Mambrini, A, Nannizzi, S, Orlandi, M, Tartarini, R, Del Freo, A, Del Tacca, M, Danesi, R & Cantore, M 2009, ' Single Nucleotide Polymorphisms and Clinical Outcome in Patients with Biliary Tract Carcinoma Treated with Epirubicin, Cisplatin and Capecitabine ', Anticancer Research, vol. 29, no. 5, pp. 1835-1840 .

مصطلحات موضوعية: Adult, Aged, 80 and over, Male, Middle Aged, Endonucleases, Deoxycytidine, Polymorphism, Single Nucleotide, Biliary tract carcinoma, DNA-Binding Proteins, Biliary Tract Neoplasms, Treatment Outcome, X-ray Repair Cross Complementing Protein 1, Antineoplastic Combined Chemotherapy Protocols, capecitabine, cisplatin, Humans, Female, Fluorouracil, Cisplatin, Capecitabine, Aged, Epirubicin, Xeroderma Pigmentosum Group D Protein

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2d33525115f40fac54ece06c418ad968Test
https://pubmed.ncbi.nlm.nih.gov/19443413Test

المؤلفون: I. Garassino, Jose A. Rodriguez, Giovanni Luca Ceresoli, Giuseppe Giaccone, Armando Santoro, Paolo Andrea Zucali, Paolo M. Comoglio, Elisa Giovannetti, Massimo Roncalli, Karijn Floor, Annarita Destro, Marielle Gallegos Ruiz, Marileila Varella-Garcia

المساهمون: Medical oncology laboratory, Medical oncology, CCA - Innovative therapy

المصدر: Ann Oncol
Annals of Oncology, 19(9), 1605-1612. Oxford University Press
Zucali, P A, Ruiz, M G, Giovannetti, E, Destro, A, Varella-Garcia, M, Floor, K, Ceresoli, G L, Rodriguez, J A, Garassino, I, Comoglio, P, Roncalli, M, Santoro, A & Giaccone, G 2008, ' Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors ', Annals of Oncology, vol. 19, no. 9, pp. 1605-1612 . https://doi.org/10.1093/annonc/mdn240Test

مصطلحات موضوعية: Male, Lung Neoplasms, Kaplan-Meier Estimate, medicine.disease_cause, Tyrosine-kinase inhibitor, Cohort Studies, chemistry.chemical_compound, Carcinoma, Non-Small-Cell Lung, In Situ Hybridization, Fluorescence, Biopsy, Needle, Gefitinib, Hematology, Middle Aged, Protein-Tyrosine Kinases, Immunohistochemistry, ErbB Receptors, Gene Expression Regulation, Neoplastic, Treatment Outcome, Oncology, Female, KRAS, Growth inhibition, medicine.drug, medicine.drug_class, Blotting, Western, medicine, Humans, Lung cancer, neoplasms, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Probability, Proportional Hazards Models, business.industry, Cancer, medicine.disease, Survival Analysis, respiratory tract diseases, lung cancer, chemistry, Drug Resistance, Neoplasm, Multivariate Analysis, Mutation, Cancer research, Quinazolines, Drug Screening Assays, Antitumor, business, Progressive disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4970f6bb5f4cef2f3972f8facf3929Test
https://europepmc.org/articles/PMC7360138Test/